Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1

76Citations
Citations of this article
85Readers
Mendeley users who have this article in their library.

Abstract

Oncogenic fusion proteins, such as EWS-FLI1, are excellent therapeutic targets as they are only located within the tumor. However, there are currently no agents targeted toward transcription factors, which are often considered to be 'undruggable.' A considerable body of evidence is accruing that refutes this claim based upon the intrinsic disorder of transcription factors. Our previous studies show that RNA Helicase A (RHA) enhances the oncogenesis of EWS-FLI1, a putative intrinsically disordered protein. Interruption of this protein-protein complex by small molecule inhibitors validates this interaction as a unique therapeutic target. Single enantiomer activity from a chiral compound has been recognized as strong evidence for specificity in a small molecule-protein interaction. Our compound, YK-4-279, has a chiral center and can be separated into two enantiomers by chiral HPLC. We show that there is a significant difference in activity between the two enantiomers. (S)-YK-4-279 is able to disrupt binding between EWS-FLI1 and RHA in an immunoprecipitation assay and blocks the transcriptional activity of EWSFLI1, while (R)-YK-4-279 cannot. Enantiospecific effects are also established in cytotoxicity assays and caspase assays, where up to a log-fold difference is seen between (S)-YK-4-279 and the racemic YK-4-279. Our findings indicate that only one enantiomer of our small molecule is able to specifically target a protein-protein interaction. This work is significant for its identification of a single enantiomer effect upon a protein interaction suggesting that small molecule targeting of intrinsically disordered proteins can be specific. Furthermore, proving YK-4-279 has only one functional enantiomer will be helpful in moving this compound towards clinical trials. © Barber-Rotenberg et al.

Author supplied keywords

References Powered by Scopus

A short history of SHELX

84447Citations
5698Readers

This article is free to access.

Get full text
Get full text

Cited by Powered by Scopus

644Citations
923Readers
Get full text
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Barber-Rotenberg, J. S., Selvanathan, S. P., Kong, Y., Erkizan, H. V., Snyder, T. M., Peter Hong, S., … Toretsky, J. A. (2012). Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget, 3(2), 172–182. https://doi.org/10.18632/oncotarget.454

Readers over time

‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘2405101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 31

61%

Researcher 12

24%

Professor / Associate Prof. 8

16%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 19

38%

Medicine and Dentistry 12

24%

Biochemistry, Genetics and Molecular Bi... 12

24%

Chemistry 7

14%

Save time finding and organizing research with Mendeley

Sign up for free
0